https://scholars.lib.ntu.edu.tw/handle/123456789/525035
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | LI-CHIEH WANG | en_US |
dc.contributor.author | JYH-HONG LEE | en_US |
dc.contributor.author | YAO-HSU YANG | en_US |
dc.contributor.author | YU-TSAN LIN | en_US |
dc.contributor.author | BOR-LUEN CHIANG | en_US |
dc.creator | Wang L.-C.;Jyh-Hong Lee;Yang Y.H.;Lin T.-Y.;Chiang B.-L. | - |
dc.date.accessioned | 2020-12-08T08:20:31Z | - |
dc.date.available | 2020-12-08T08:20:31Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0929-8673 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34347341760&doi=10.2174%2f092986707780830961&partnerID=40&md5=6d73b02ba0c3650945bd4c81375efa1b | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/525035 | - |
dc.description.abstract | Asthma is characterized by airway inflammation, bronchial hyper-responsiveness, and reversible airway obstruction. Medications for asthma include corticosteroids, β2-adrenergic receptor agonists, chromones, methylxanthines, and leukotriene modifiers. Despite these advances in therapy, many symptoms are not well controlled. Since asthma is a chronic airway inflammation with a bias towards a type 2 T helper (Th2) cell response, some new approaches are targeted towards the Th2 inflammation pathway. These include anti-IgE therapy, anti-Th2 cytokine therapy, and therapies aiming at increasing Th1 cytokines. This article will focus on DNA-based therapy, a novel therapeutic strategy for asthma. Immunostimulatory gene therapy using CpG oligodeoxynucleotides with central deoxycytidyl-deoxyguanosine (CpG) dinucleotide, in which the cytosine nucleobase is unmethylated, can stimulate the innate immunity and augment Th1 response. With DNA gene therapy, genes can be introduced to target Th1 cytokines or other mediators in the airway in order to counteract Th2 inflammation in asthma. Also, antisense oligonucleotides can target mRNA species of interest in asthma. Through these therapies, we can expect long-lasting effects, better control of symptoms, and reducing medication in the future. ? 2007 Bentham Science Publishers Ltd. | - |
dc.relation.ispartof | Current Medicinal Chemistry | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | adenovirus vector; antiasthmatic agent; antisense oligodeoxynucleotide; beta adrenergic receptor stimulating agent; chromone derivative; CpG oligodeoxynucleotide; cytokine receptor antagonist; eotaxin; epi 2010; FAS ligand; Flt3 ligand; galectin 3; gamma interferon; glucocorticoid; interleukin 1 receptor blocking agent; interleukin 10; interleukin 12; interleukin 18; interleukin 4 receptor blocking agent; interleukin 5; iss 1018; leukotriene derivative; liposome; methylxanthine derivative; oligodeoxynucleotide phosphorothioate; omalizumab; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; polylysine; transforming growth factor beta; unclassified drug; unindexed drug; aerosol; allergy; asthma; autoimmune disease; blood clotting disorder; blood clotting time; cardiovascular disease; clinical trial; complement activation; disease exacerbation; drug distribution; drug formulation; drug half life; drug safety; drug structure; drug targeting; drug tolerability; gene targeting; gene therapy; genetic transfection; human; hypotension; immunotherapy; nebulizer; nonhuman; nonviral gene delivery system; review; RNA interference; side effect; structure analysis; Th1 cell; Th2 cell; viral gene delivery system; Adjuvants, Immunologic; Animals; Asthma; DNA; Gene Therapy; Humans; Oligonucleotides; Oligonucleotides, Antisense; RNA Interference; RNA, Small Interfering | - |
dc.title | New biological approaches in asthma: DNA-based therapy | en_US |
dc.type | review | en |
dc.identifier.doi | 10.2174/092986707780830961 | - |
dc.identifier.pmid | 17584068 | - |
dc.identifier.scopus | 2-s2.0-34347341760 | - |
dc.relation.pages | 1607-1618 | - |
dc.relation.journalvolume | 14 | - |
dc.relation.journalissue | 15 | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | review | - |
item.grantfulltext | none | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Pediatrics | - |
crisitem.author.dept | Pediatrics-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Oral Biology | - |
crisitem.author.dept | College of Life Science | - |
crisitem.author.dept | Immunology | - |
crisitem.author.orcid | 0000-0002-5773-1627 | - |
crisitem.author.orcid | 0000-0003-4285-4912 | - |
crisitem.author.orcid | 0000-0002-6266-9864 | - |
crisitem.author.orcid | 0000-0002-4192-3165 | - |
crisitem.author.orcid | 0000-0002-6705-0286 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。